We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Resveratrol on Age-related Insulin Resistance and Inflammation in Humans

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01354977
Recruitment Status : Unknown
Verified May 2011 by Albert Einstein College of Medicine, Inc..
Recruitment status was:  Recruiting
First Posted : May 17, 2011
Last Update Posted : May 17, 2011
Sponsor:
Information provided by:

Study Description
Brief Summary:
The purpose of this research is to study the effects of a medication called resveratrol on the body's response to insulin (a hormone to control blood sugar), on inflammation and/or on specific cells and processes in fat tissue, and on skeletal muscle metabolism and on brain function.

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Mellitus Insulin Resistance Drug: Resveratrol Phase 2

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effect of Resveratrol on Age-related Insulin Resistance and Inflammation in Humans
Study Start Date : March 2008
Estimated Primary Completion Date : March 2015

Resource links provided by the National Library of Medicine

Drug Information available for: Resveratrol
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: Resveratrol
Resveratrol
Drug: Resveratrol
1,000mg twice daily for 28 days


Outcome Measures

Primary Outcome Measures :
  1. Peripheral Insulin Sensitivity [ Time Frame: Four weeks ]
    We will measure peripheral insulin sensitivity by determining the rate of glucose uptake


Secondary Outcome Measures :
  1. Hepatic insulin sensitivity [ Time Frame: 4 weeks ]
    Endogenous glucose production will be used to determine hepatic insulin sensitivity

  2. Muscle mitochondrial function [ Time Frame: 4 weeks ]
    Muscle mitochondrial structure by electron microscopy and function by enzymatic assays.

  3. Inflammatory and Anti-inflammatory Markers in adipose tissue [ Time Frame: 1 month ]
    Inflammatory Markers: PAI-1, IL-6, TNF-a, iNOS Anti-inflammatory Markers: Adiponectin, Arginase 1 Will be measured in plasma

  4. Neuropsychological assessment [ Time Frame: pre and post clamp studies (4 weeks) ]
    Neuropsychological testing will be performed to assess cognitive function.


Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   45 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • BMI: 26-35
  • Non-smoker
  • Normal screening labs (CMC, chemistry, LFTs PT/PTT)
  • No CAD
  • Good IV access

Exclusion Criteria:

  • High cholesterol
  • <4 week history of participation in another drug trial
  • Severe hypertension
  • Heart disease
  • Liver disease of liver abnormalities
  • Cerebrovascular disease, i.e. stroke
  • CVD
  • Seizures
  • Bleeding disorders
  • Muscle disease
  • Cancer
  • HIV
  • Hepatitis (all types)
  • Mentally disabled persons
  • Pregnant women
  • Allergies to Novocaine, Lidocaine, Benzocaine
  • Subjects on the following medications:

    • Anticoagulant and antiplatelet drugs
    • Anti-epileptic drugs
    • Mexiletene
    • Quinidine
    • Cyclosporine
    • Tacrolimus
    • HIV protease inhibitors
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01354977


Contacts
Contact: Stephanie Lawrence 718-430-2903 stephanie.lawrence@einstein.yu.edu

Locations
United States, New York
Albert Einstein College of Medicine Recruiting
Bronx, New York, United States, 10461
Contact: Stephanie Lawrence    718-430-2903    stephanie.lawrence@einstein.yu.edu   
Principal Investigator: Preeti Kishore, MD         
Sponsors and Collaborators
Albert Einstein College of Medicine, Inc.
More Information

Responsible Party: Preeti Kishore, M.D., Albert Einstein College of Medicine
ClinicalTrials.gov Identifier: NCT01354977     History of Changes
Other Study ID Numbers: 2007-534
First Posted: May 17, 2011    Key Record Dates
Last Update Posted: May 17, 2011
Last Verified: May 2011

Keywords provided by Albert Einstein College of Medicine, Inc.:
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Diabetes Mellitus
Endocrin System Diseases
Resveratrol
Therapeutic Uses

Additional relevant MeSH terms:
Diabetes Mellitus
Inflammation
Diabetes Mellitus, Type 2
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Pathologic Processes
Hyperinsulinism
Resveratrol
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents
Enzyme Inhibitors
Platelet Aggregation Inhibitors
Antimutagenic Agents
Anticarcinogenic Agents